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ABSTRACT
Solid organ transplantation is a significant development in the treatment of chronic kidney, liver, heart and lung diseases. This therapeutic 
approach has increased patient survival and improved quality of life. New surgical techniques and immunosuppressive drugs have been 
developed to achieve better outcomes. However, the variety of neurological complications following solid organ transplantation is broad 
and carries prognostic significance. Patients may have involvement of the central or peripheral nervous system due to multiple causes that 
can vary depending on time of onset after the surgical procedure, the transplanted organ, and the intensity and type of immunosuppressive 
therapy. Neurological manifestations following solid organ transplantation pose a diagnostic challenge to medical specialists despite 
extensive investigation. This review aimed to provide a practical approach to help neurologists and clinicians assess and manage solid 
organ transplant patients presenting with acute or chronic neurological manifestations.     
Keywords: organ transplantation; neurological manifestations; central nervous system; peripheral nervous system. 
RESUMO
O transplante de órgãos sólidos é um importante avanço no tratamento de doenças crônicas renal, hepática e cardíaca. Esta terapia tem 
aumentado a sobrevida e melhorado a qualidade de vida dos pacientes. Novas técnicas cirúrgicas e imunossupressores tem sido desenvolvidos 
para alcançar melhores desfechos. Entretanto, a variedade de complicações neurológicas que acompanham o transplante de órgãos sólidos 
é ampla, e carrega significado prognóstico. Pacientes podem ter acometimento do sistema nervoso central ou periférico devido a múltiplas 
causas que podem variar conforme o tempo após a realização da cirurgia, órgão transplantado e grau e tipo de terapia de imunossupressão. 
Manifestações neurológicas após o transplante de órgãos sólidos representam um desafio diagnóstico para médicos especialistas apesar 
de extensa investigação. O objetivo desta revisão é oferecer uma abordagem prática para ajudar neurologistas e clínicos a avaliar e manejar 
pacientes com transplante de órgãos sólidos que se apresentem com manifestações neurológicas agudas ou crônicas. 
Palavras-chave: transplante de órgãos; manifestações neurológicas; sistema nervoso central; sistema nervoso periférico.
Solid organ transplantation is a significant development 
in the treatment of chronic kidney, liver, heart and lung dis-
eases. This therapeutic approach has increased patient sur-
vival and improved quality of life. New surgical techniques 
and immunosuppressive drugs have been developed to 
achieve better outcomes1.
Despite this major medical breakthrough, several com-
plications may arise from transplantation. Neurological 
complications in solid-organ transplant patients may 
occur immediately after the surgical procedure, or after 
months or years, and increase morbidity and mortality 
in these patients2. The main neurological complications 
include infections, neoplasms, seizures, vascular disorders, 
psychiatric disorders and cognitive impairment, metabolic 
disturbances, and adverse drug reactions (Table 1). 
This review aimed to provide a practical approach to help 
neurologists and clinicians assess and manage solid organ 
transplant patients presenting with acute or chronic neuro-
logical manifestations.  
CENTRAL NERVOUS SYSTEM INFECTIONS
Organ transplant recipients have a high risk of oppor-
tunistic infections and the central nervous system (CNS) 
is frequently involved. However, in recent years, there has 
been a reduction in cases of opportunistic infections after 
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organ transplantation3. This is a consequence of effective 
prophylactic strategies against opportunistic pathogens 
and a more prudent management for immunosuppression3. 
Headache, low-grade fever and mental status impairment 
are the most common clinical symptoms caused by oppor-
tunistic infections in organ transplant recipients4,5.
In the early post-transplant period (one to two months), 
the most common infections are derived from the hospi-
tal environment. After the first month, viral infections pre-
dominate. Tardive infections may include: Mycobacterium 
tuberculosis, Trypanosoma cruzi, Leishmania species, 
Strongyloides stercoralis, Cryptococcus neoformans, 
Histoplasma capsulatum, Coccidioides and species of 
Paracoccidioides6,7,8,9.
Table 1. Main neurological complications in solid organ 
transplant patients.
Central nervous system infections
Viral infections (herpes virus family and polyomavirus)
Bacterial infections (Nocardiosis, Listeria monocytogenes and 
Mycobacterium tuberculosis)
Fungal infections (Aspergillus, Mucormycosis, Cryptococcosis)
Protozoan infections (Toxoplasmosis)
Neuromuscular complications
Neuropathy
Myopathy
Neuromuscular junction disorders
Seizures
Immunosuppressant toxicity
Metabolic changes
Infections
Stroke
Tumors
Vascular neurologic complications
Posterior reversible encephalopathy syndrome (PRES)
Ischemic stroke
Intracerebral hemorrhage
Reversible cerebral vasoconstriction syndrome
Psychiatric and behavioral disorders
Depression
Anxiety
Bipolar disorders
Psychosis
Delirium
Substance abuse
Central nervous system post-transplant lymphoproliferative 
disorders (PTLD)
Neurological complications of immunosuppressive agents 
(Details in Table 3)
Other neurological manifestations
Altered consciousness and encephalopathy
Central pontine myelinolysis
Graft-versus-host disease
Myelopathies
Movement disorders
Headache
Visual and auditory disturbances
Differential diagnosis of infection in solid organ 
causative of transplantation patients
It is essential to differentiate the causative pathogens 
causative of the neurological condition given specific treat-
ment varies and mortality is high. Neuroimaging features 
may contribute to the diagnosis10. Table 2 describes, in detail, 
the main infections associated with solid organ transplanta-
tion patients11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28.
Viral infections
Viral infection of the CNS in post-transplantation 
patients can be divided into two etiological groups: human 
herpes virus family (herpes simplex virus [HSV], cytomeg-
alovirus [CMV], Epstein-Barr virus [EBV], varicella-zoster 
virus [VZV], human herpes virus type 6 [HHV-6] and human 
herpes virus type 7 [HHV-7]) and polyomavirus13,14,15,16,17,18.
Neurological manifestations include limbic encephalitis-like 
syndrome (HSV, CMV, HHV-6), rhombencephalitis, ventriculitis, 
myelitis, vascular involvement (VZV), and a multisystem post-
transplant lymphoproliferative disorder (PTLD), which may 
involve the CNS and is associated with the EBV. 13,14,15,16,17,18.
Progressive multifocal leukoencephalopathy leads to demy-
elination after opportunistic infection of the JC virus5. The 
symptoms usually appear in the first year after transplanta-
tion, and include focal neurological deficit, sudden loss of con-
sciousness and visual changes. The brain MRI shows asymmet-
ric, non-enhancing, T2 hyperintense lesions –  usually in the 
subcortical regions (Figure 1).5 Cerebrospinal fluid (CSF) poly-
merase chain reaction (PCR) for JC virus can yield the diagnosis 
with sensitivity of approximately 75%.5
Bacterial infections
The main bacterial infections in immunosuppressed 
patients include nocardiosis, Listeria monocytogenes and 
Mycobacterium tuberculosis. 
Nocardiosis is rare and may occur in up to 3.5% of trans-
plant recipients21.  High-dose corticosteroids are the major 
risk factor for this infection11,21. Brain abscess is the most 
common finding of this CNS infection (Figure 2) and common 
Figure 1. Brain MRI discloses subcortical lesions (hyperintense 
signal) with cortical preservation in a patient with JC virus infection.
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symptoms of nocardiosis include fever, headache, impair-
ment of consciousness and seizures. Treatment includes tri-
methoprim–sulfamethoxazole, imipenem or a third-genera-
tion cephalosporin and amikacin21.
Listeria monocytogenes  infection may cause meningitis 
or meningoencephalitis, presenting with fever, headache, 
altered mental status and seizures22.  Cranial neuropathies, 
dysarthria, paresis, and ataxia occur in approximately 40% 
due to brainstem involvement (rhombencephalitis)10,22. CSF 
analysis usually demonstrates polymorphonuclear or lym-
phocytic pleocytosis with elevated protein levels, and hypo-
glycorrhachia.  Listeria monocytogenes  can be identified on 
the CSF gram stain in only 30–40% of cases10,22.
Mycobacterium tuberculosis  infection Symptoms of 
Mycobacterium include fever and altered mental status9,23. 
Meningitis can be complicated by hydrocephalus and vasculop-
athy. The MRI scans typically demonstrate meningeal enhance-
ment. Abscesses and tuberculomas may be accompanied by 
ring enhancement with surrounding edema (Figure 3). PCR 
assay is the recommended method to investigate infection with 
moderate sensitivity and high specificity. Empiric treatment is 
warranted when CNS tuberculosis is suspected, and a four-drug 
regimen can be administered including isoniazid, rifampicin, 
ethambutol, and pyrazinamide23.
Fungal infections
CNS infection caused by Aspergillus is clinically charac-
terized by changes in consciousness, seizures, focal neuro-
logical deficit and, less commonly, meningitis and subarach-
noid hemorrhage due to a mycotic aneurysm. Abscesses 
appear preferentially in the frontal and parietal lobes3, but 
the cerebellum and brainstem can also be affected (Figure 4). 
Cerebral ischemia and hemorrhages may also appear due to 
vascular injuries from Aspergillus3.
Cryptococcosis is a common late complication of trans-
plant with subacute or chronic meningitis26. Meningismus 
is infrequent; however, increased intracranial pressure often 
occurs. Diagnosis is based on rapid antigen detection in the 
CSF and serum and isolation of the pathogen in CSF culture. 
Induction therapy consists of lipid formulations of ampho-
tericin B plus flucytosine for at least two weeks followed by 
consolidation and maintenance therapy with fluconazole26.
Protozoan infections
Toxoplasmosis occurs by reactivation of latent infec-
tion, after ingestion of contaminated food. Toxoplasma gondii 
lesions are frequently located in the basal ganglia and brain tis-
sue with ring-enhancing abnormalities, edema or hemorrhage 
seen on MRI. Toxoplasmic meningoencephalitis is infrequently 
seen and may occur in the first three months after transplant. 
Empiric therapy with sulfadiazine and pyrimethamine is rec-
ommended on suspected infection. A presumptive diagnosis 
is based on seropositivity, clinical presentation, characteris-
tic imaging, and response to therapy. The CSF analysis shows 
elevated toxoplasma-specific IgG titers or evidence of toxo-
plasma DNA, but a definite diagnosis can only be provided by 
histopathology, which is hardly ever necessary27.
Figure 2. Multiple brain abscess in a patient with nocardiosis of the central nervous system. 
Figure 3. Axial-T1 weighted brain MRI shows multiple lesions 
at the base of the skull with gadolinium enhancement in a 
patient with tuberculosis of the nervous system. 
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NEUROMUSCULAR COMPLICATIONS 
Neuropathies and myopathies are unusual complica-
tions following solid-organ transplantation. The reported fre-
quency of neuromuscular disorders was 1%-13% in series of 
heart transplantation, 4% after liver grafting and up to 21% in 
lung recipients1,2.
Mononeuropathy, plexopathy and polyneuropathy are 
likely associated with surgical and clinical complications 
following engraftment and immunosuppresion. In addition, 
prior organ failure, toxic and metabolic disturbances preced-
ing the transplantation (diabetes, uremia, and alcohol intake) 
may predispose this patient population to nerve damage.5 
Surgical positioning and manipulation can lead to entrap-
ment neuropathies (such as ulnar neuropathy and femoral 
neuropathy) or lower trunk brachial plexopathy following 
stretching stress related to thoracotomy in lung and heart 
transplantation. Lumbosacral plexopathy after kidney trans-
plantation has also been described1,2.  
Phrenic mononeuropathy has been associated with 
delayed weaning from mechanical ventilation in combined 
heart-lung or isolated lung transplant patients, who can 
also present with recurrent laryngeal nerve injury. Femoral 
neuropathy has been related to kidney transplantation; and 
peroneal, ulnar, and median nerve dysfunction have been 
described after solid organ transplantation1,2.
Immunosupressant drug toxicity is an uncommon cause 
of polyneuropathy. Case reports have described acute or 
chronic sensorimotor axonal polyneuropathy after tacroli-
mus tacrolimus exposure, with symptom improvement after 
drug discontinuation25. Cyclosporine has also been associ-
ated with axonal polyneuropathy in a few case reports2.
Acute inflammatory demyelinating polyneuropathy or 
polyradiculopathy, also known as Guillain-Barré syndrome, 
in solid organ transplant patients has been associated with 
Campylobacter jejuni infection, as well as with cyclosporine 
neurotoxicity and prior or active CMV infection. Treatment 
includes intravenous immunoglobulin or plasmapheresis, sub-
stitution of the immunosuppressant drug or treatment with 
ganciclovir in selected cases26. An association between tacroli-
mus and Guillain-Barré syndrome after organ transplantation 
is not yet clear.
In a prospective study, chronic inflammatory demyelinat-
ing polyneuropathy (CIDP) was confirmed in 0.6% of 1,557 solid 
organ transplant recipients during eight years of follow-up. 
CIDP developed within the first year after liver, kidney, heart 
or lung transplantation. Immunosuppressive dose reduc-
tion before CIDP onset was reported in 60% of cases. Clinical 
improvement was achieved after treatment with intravenous 
immunoglobulin alone or combined with optimized immuno-
supressive therapy.31 In addition to axonal injury, cyclosporine 
and tacrolimus toxicity has been implicated in sensorimotor 
demyelinating polyneuropathy resembling CIDP.27
Clinical complications following transplantation that 
require critical care support, neuromuscular junction block-
ing agents and steroid exposure (especially intravenously) 
are risk factors for critical illness myopathy and critical ill-
ness polyneuropathy. In addition, in critical care settings, the 
use of linezolid and other drugs can be associated with toxic 
neuropathy2. Critical illness myopathy manifests as difficulty 
in weaning from mechanical ventilation, subacute weakness 
while sparing eye movements, or even acute severe quadripa-
resis reported after liver transplantation28.
Multiple factors are associated with the development of 
myopathy in transplant recipients. Myositis and rhabdomyolysis 
are frequently drug induced (azathioprine; combination of cyclo-
sporine with colchicine or statin in kidney transplant recipients), 
associated with viral infections, or secondary to electrolyte imbal-
ance. An inflammatory myopathy similar to idiopathic polymy-
ositis with elevated serum creatine kinase has been reported 
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Figure 4. Brain abscess caused by Aspergillus involving the cerebellum in a transplant recipient. 
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following renal transplantation, and was successfully treated with 
high-dose steroid therapy. Myopathy secondary to steroid use has 
an insidious onset and normal creatine kinase levels.
Neuromuscular junction transmission impairment is not 
consistently reported in solid organ transplant recipients, in 
contrast to reports of myasthenia gravis following chronic graft-
versus-host disease in hematopoietic stem cell transplanta-
tion.28 Prolonged paralysis after neuromuscular junction block-
ade has been rarely reported in solid organ transplantation.28
SEIZURES
Seizures are common neurological complications after organ 
transplantation. They occur in 5–10% of transplant patients and 
are generally indicative of a metabolic or structural brain dis-
order29. The most common causes of seizures are immunosup-
pressant toxicity (especially associated with OKT3 and cyclo-
sporine), metabolic changes, infections, stroke, and tumors4,29.
Seizures most frequently occur within the first few weeks 
after transplant and may be generalized or partial, and are 
usually tonic-clonic4. Seizures associated with drug toxicity 
are preceded by subtle mental and behavioral changes and are 
often transient requiring no treatment other than reduction 
of toxic drugs. Although status epilepticus is rare, the clinical 
diagnosis may sometimes prove difficult and an EEG should 
be obtained if the patient remains unresponsive after the sei-
zure. The differential diagnosis of seizures include delirium or 
non-epileptic movements like myoclonus ( focal or multifocal) 
and tremors, usually secondary to metabolic or drug-induced 
derangements4,29.
Patient evaluation should include MRI, CT scans, measure-
ment of immunosuppressive drug levels, EEG and laboratory 
tests (sodium, calcium, magnesium and glucose). Additional 
tests include CSF analysis if an infection is suspected29.
Patients who have had a single seizure should not be 
treated with antiepileptic drugs, especially if a rapidly revers-
ible cause is identified on laboratory tests (e.g., hyponatremia 
or hypoglycemia). Benzodiazepines are the first-line agents 
used after the first seizure, and if patients require long-term 
treatment, other drugs may be selected4,29.
Long-term treatment with antiepileptic drugs needs to be 
selected by a doctor, with the patient’s consent, based on the 
etiology of the seizures, because it requires close monitoring 
of immunosuppressive therapy due to drug-drug interactions. 
The most traditional antiepileptic drugs (phenobarbital, phe-
nytoin and carbamazepine) interfere with the metabolism of 
commonly-used immunosuppressive agents because of the 
induction of the hepatic cytochrome  P450 system. Serum 
proteins (in particular, albumin) may be modified by several 
underlying clinical conditions, such as nutrition, drug inter-
action and electrolyte changes in transplanted patients; thus, 
monitoring of antiepileptic drug levels is recommended. The 
use of valproate should be avoided in liver transplant patients 
because of potential hepatotoxicity.  Phenytoin has commonly 
been used (can be loaded intravenously), while gabapentin 
and levetiracetam should be considered as oral medications 
for their lack of hepatic enzyme induction and minimal inter-
actions with immunosuppressive drugs4,29.
The prognosis is usually favorable when a treatable and 
reversible cause is identified, but it is poor when a severe or irre-
versible cause, such as a tumor or systemic illness, is identified4,29.
VASCULAR NEUROLOGIC COMPLICATIONS 
Posterior reversible encephalopathy syndrome
Posterior reversible encephalopathy syndrome (PRES) 
is a neurotoxic state accompanied by a unique brain imag-
ing pattern typically associated with a number of complex 
Figure 5. Patient with posterior reversible encephalopathy syndrome (PRES). The MRI demonstrates focal areas of symmetric 
brain edema with predominant involvement of posterior lobes. 
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clinical conditions including eclampsia/preeclampsia, allo-
genic bone marrow transplantation, solid organ transplan-
tation, autoimmune diseases and chemotherapy. Posterior 
reversible encephalopathy syndrome is a leading neurologi-
cal complication in solid organ transplantation, particularly 
in patients who have received tacrolimus or cyclosporin A.30
Clinical symptoms are broad and include headache, vision 
changes, paresis, hemianopsia, nausea, and altered mental sta-
tus, which usually develop over a couple of days. Approximately 
70% of patients present with hypertension. The syndrome occurs 
in 0.4–6% of solid organ transplant recipients, sometimes follow-
ing infection or transplant rejection. Among kidney transplant 
recipients, PRES is typically a late complication, which develops 
in a setting of poorly-controlled hypertension and is associated 
with less extensive brain edema. In liver transplant recipients, 
PRES has an early onset (less than two months after transplan-
tation) and is associated with extensive brain edema30.
Brain imaging typically demonstrates focal areas of sym-
metric brain hemispheric edema (Figure 5). The parietal and 
occipital lobes are most commonly affected, followed by the 
frontal lobes, the inferior temporal-occipital junction and the 
cerebellum. Lesion confluence may develop as the extent of 
edema increases30.
Treatment of PRES involves identifying and treating the 
underlying precipitating factor as well as brain edema and sei-
zures. In transplant recipients, calcineurin inhibitors should 
be discontinued or, controversially, reduced. Symptoms and 
brain lesions will resolve in many cases, however irrevers-
ible damage may occur in selected patients in whom PRES is 
complicated by cerebral infarction or hemorrhage30.
Stroke
Ischemic stroke and intracerebral hemorrhage have been 
reported as complications of both solid organ transplanta-
tion and hematopoietic stem cell transplantation. They typi-
cally occur in the setting of hypertension, diabetes, cardiac 
arrhythmias, coagulation disturbances, bacterial endocardi-
tis, and accelerated atherosclerosis, which may be pre-exist-
ing or develop after transplantation.31
Ischemic strokes are more common after heart transplan-
tation, with an incidence rate of 2-10%31. Higher stroke rates 
in cardiac transplant recipients are specifically associated with 
advanced age, diabetes mellitus, valvular disease as the indication 
for heart transplantation, preoperative use of left ventricular assist 
devices or intra-aortic balloon pump, and a prolonged cardiopul-
monary bypass time31. Strokes occur in 2–3% of lung transplant 
recipients, whereas 5–10% of kidney transplant recipients may 
have a stroke due to the high burden of cardiovascular risk factors. 
Ischemic stroke is rare in liver transplant recipients, with an 
estimated rate of 0-3%. However, because of underlying coagu-
lopathy and thrombocytopenia, these patients have a higher 
risk of intracranial hemorrhage, with mortality rates of up to 
80%. Intracranial hemorrhage is a late complication in kidney 
transplant patients and is rare in cardiac transplant recipients31.
Reversible cerebral vasoconstriction syndrome
Reversible cerebral vasoconstriction syndrome com-
prises a group of conditions characterized by reversible mul-
tifocal narrowing of the cerebral arteries heralded by sudden 
(thunderclap), severe headaches with or without associated 
neurologic deficits32. Misdiagnose as primary cerebral vascu-
litis and aneurysmal subarachnoid hemorrhage is common 
because of overlapping clinical and angiographic features. 
However, unlike these more ominous conditions, reversible 
cerebral vasoconstriction syndrome is usually self-limited 
and headaches and vasoconstriction resolve over a period of 
days to weeks32.
Reversible cerebral vasoconstriction syndrome includes 
Call-Fleming syndrome, migraine angiitis, postpartum angiopa-
thy, and drug-induced vasospasm. Among the drugs associated 
with this syndrome are tacrolimus, cocaine, ecstasy, amphet-
amine derivatives, marijuana, cyclophosphamide, erythropoi-
etin and intravenous immunoglobulins. Diagnostic criteria 
include the presence of segmental cerebral artery vasoconstric-
tion in digital transfemoral angiography or indirect (CT or MRI) 
angiography; no evidence of aneurysmal subarachnoid hemor-
rhage; normal or near-normal CSF analysis (< 10 cells, protein 
< 80 mg and normal glucose level); severe acute headache with 
or without neurological signs or symptoms; and reversibility of 
angiographic abnormalities within 12 weeks32.
PSYCHIATRIC AND BEHAVIORAL DISORDERS
Transplantation provides life-saving therapy to critically 
ill patients with end-stage organ failure. Specialized knowl-
edge of mental health disorders is essential for optimal care 
of these patients33.
Solid organ transplant recipients are at increased risk of 
a range of psychiatric complications including anxiety dis-
orders, mood disorders, and psychosis. Common presenta-
tions include post-traumatic stress disorder, depression and 
anxiety states, mania, psychosis, delirium, and drug abuse. 
Patients with pretransplant psychiatric comorbidities are 
at particular risk of decompensation. Calcineurin inhibi-
tor agents and corticosteroids may have very prominent 
behavioral effects33. We describe below the main psychiatric 
comorbidities seen in transplant recipients.
Depression
Depressive symptoms can affect the medical outcome of 
numerous conditions including cardiovascular diseases, dia-
betes mellitus, chronic obstructive pulmonary disease as well 
as kidney, heart or liver transplantation. Depressive symp-
toms have consistently been shown to be associated with 
higher mortality in these patients33.
Cytomegalovirus infection and graft rejection are two of 
the most common causes of acute post-transplant depres-
sion33. Depression is also seen in the setting of bacterial 
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sepsis, abscess formation, diarrhea, fungal infection, herpes 
simplex encephalitis, tuberculosis, and cryptococcal infec-
tion. It is also a common finding in hepatitis C virus-related 
cirrhosis and a common complication of antiviral therapy33.
Excessive weight gain or loss, altered immune function, 
increase in sedentary behaviors, changes in information 
processing, diminished perception of self-worth, unemploy-
ment, lethargy, pain and fatigue are among the factors that 
could cause depressive symptoms and interfere with motiva-
tion during rehabilitation33.
Depression is treated with combined psychotherapy 
and psychopharmacology. The efficacy of medications may 
not be evident for six to eight weeks.  It is important to con-
sider long-term treatment for those with severe depression. 
Electroconvulsant therapy may be required in severe cases. 
The most commonly-used antidepressants are selective sero-
tonin reuptake inhibitors. Patients with depression should 
not be excluded from transplantation, but it highlights the 
importance of preoperative assessment and treatment of this 
condition to optimize post-operative outcomes33.
Anxiety
Anxiety is very common when post-transplant recipients 
are getting close to being discharged from hospital. They may 
have concerns about not being continuously observed by the 
transplant team33.
Post-traumatic stress disorder may occur in response to 
organ transplantation events. Patients may experience delu-
sions or hallucinations of life-threatening events related to 
their medical condition. Symptoms also include flashbacks, 
enhanced startle response and nightmares33.
Benzodiazepines are helpful for immediate relief of anx-
iety and for prevention of panic attacks. The risk of depen-
dency is of special concern in patients with a history of 
substance abuse. Buspirone is a good drug choice in these 
cases. Selective serotonin reuptake inhibitors and cognitive 
behavioral therapy are indicated for patients with persist-
ing anxiety disorders33.
Psychosis
The occurrence of hospitalized psychoses has indepen-
dently been associated with increased risk of death and graft 
loss after renal transplantation, possibly mediated through 
medical non-adherence34.
Most post-transplantation psychoses may result from 
stress-related exacerbations of a primary psychiatric disor-
der or abrupt discontinuation of mood stabilizers or antipsy-
chotic medications33. In addition, several conditions predis-
pose transplanted patients to an increased risk of psychosis: 
the use of high-dose corticosteroids, chronic illness-associ-
ated affective disorders, metabolic disturbances, and other 
immunosuppressive medications used in transplantation, 
such as calcineurin inhibitors, which have known neuropsy-
chological side effects34.
Emergency psychiatric consultation is indicated when 
psychotic symptoms interfere with medical management 
or are associated with suicidal ideation. The effectiveness of 
pharmacologic management has improved with the avail-
ability of newer atypical antipsychotic agents34.
Delirium
Delirium is a sudden change in brain function and involves 
altered mental content and inattentiveness not associated 
with established dementia. Both hyperactive and hypoac-
tive subtypes may be present after transplantation. Factors 
associated with this disorder are intraoperative complica-
tions, medication toxicity including calcineurin inhibitor-
induced toxicity, drug-drug interactions, metabolic or neu-
rologic complications, infection, drug or alcohol withdrawal, 
vitamin deficiency (thiamine, folate, and B12 vitamin), endo-
crinopathy, and hematologic disorders. Haloperidol and typ-
ical antipsychotic agents are recommended for agitation, 
delusions, and active hallucinations. Excessive sedation may 
occur in patients with severe hepatic or renal failure and the 
elderly. Brain imaging, EEG, and lumbar puncture may pro-
vide important information34.
Bipolar disorders
The hallmark of this group of disorders is a propen-
sity to develop profound changes in mood and behavior. 
Patients can  do well post-transplant if their  disorders 
are previously well controlled. Nevertheless, postopera-
tive exacerbation of bipolar disorders can be triggered by 
operative stress or medical complications. A recurrence of 
life-threatening mania or depression has occurred among 
patients who had been symptom-free for as long as two 
decades. Prednisone may also precipitate hypomania, 
depression, or mixed mood disorder. A steroid-sparing 
immunosuppressive protocol is therefore indicated when 
feasible. Mood changes at any time can be unpredictable 
and disruptive to social support and doctor-patient com-
munication. Emergency psychiatric intervention may be 
necessary to deal with the life-threatening risk of medica-
tion noncompliance33.
Substance abuse
A recent meta-analysis demonstrated relapse rates as low 
as 2.5–5.6% of patients per year among transplanted individ-
uals after histories of alcohol and/or illicit drug use35. Even 
those on methadone maintenance do not appear to relapse 
often while remaining on treatment. Methadone mainte-
nance programs should not taper off methadone unless rec-
ommended by drug abuse counselors who will provide active 
follow-up support. Analgesic needs may increase because 
of tolerance or anxiety. Return to pre-established mainte-
nance levels is an appropriate goal. Morbidity from relapse of 
tobacco use is common post-transplant and requires active 
treatment referral35.
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CENTRAL NERVOUS SYSTEM POST-TRANSPLANT 
LYMPHOPROLIFERATIVE DISORDERS
Central nervous system post-transplant lymphoprolifera-
tive disorders (PTLD) represent a spectrum of diseases char-
acterized by lymphoid or plasmacytic proliferation that may 
occur in solid organ, bone marrow, or hematopoietic stem 
cell transplantation recipients. The disorder can be divided 
into a range of histological subtypes from reactive plasma-
cytic hyperplasia and polymorphic PTLD to monomorphic 
PTLD or malignant lymphoma. It is the second most com-
mon malignancy in post-transplant patients following skin 
cancer and is the first post-transplant malignancy in chil-
dren. It usually occurs within the first year after transplant 
and is associated with EBV infection. Heart, lung and intes-
tinal transplant recipients are at higher risk because they 
require intensive immunosuppression. Cyclosporine and 
tacrolimus may increase the risk of PTLD36.
Post-transplant lymphoproliferative disorders rarely 
involve the CNS causing multifocal brain lesions with either 
a ring-enhancing or homogenous pattern. The majority of 
patients have a multifocal disease with a predilection for the 
periventricular/basal ganglia region36. A third of the patients 
may present with infratentorial involvement (Figure 6). 
The differential diagnosis is broad and includes infectious 
(abscess, toxoplasmosis) and neoplastic diseases (PTLD and 
others). The decision to perform less invasive diagnostic eval-
uations or proceed immediately to biopsy is controversial36.
The optimal treatment of CNS PTLD is still not clearly 
defined. Patients may present with unaltered clinical status, 
and for that reason, the risks of treatment may be greater 
than those for immunocompetent patients with CNS lym-
phoma. Dose reduction or discontinuation of immunosup-
pressive agents is effective for approximately half of the PTLD 
patients. Radiotherapy is an option in selected patients36.
NEUROLOGICAL COMPLICATIONS OF 
IMMUNOSUPPRESSIVE AGENTS
Immunosuppressive drugs currently used in clinical prac-
tice for transplant patients may cause peripheral and central 
neurological disorders. The mechanisms include direct drug 
effects or drug interactions. Side effects related to the treat-
ment of infectious diseases are described above. Up to a third 
of transplant patients may have neurological side effects 
induced by immunosuppressive agents. The most common 
neurological manifestations include seizures, stroke, enceph-
alitis, neuropathy, and acute encephalopathy. Three clinical 
syndromes related to neurological complications of immu-
nosuppressive agents are noteworthy:  PRES, immune recon-
stitution inflammatory syndrome, and PTLD37.
The main immunosuppressive drugs for transplant 
patients are antiproliferative agents, calcineurin inhibitors and 
corticosteroids. Associated induction or maintenance drugs 
include monoclonal antibodies, polyclonal antibodies, cyclo-
phosphamide, methotrexate, intravenous immunoglobulin, 
and rituximab37. Plasmapheresis can be used to treat some 
transplant patients. Table 3 shows the main neurological 
effects related to immunosuppressive agents. 
OTHER NEUROLOGICAL MANIFESTATIONS
Altered consciousness and encephalopathy 
Alterations of consciousness and encephalopathy are 
common after transplantation with manifestations rang-
ing from confusion and delirium to stupor and coma. 
Multiple causes are involved and the spectrum of condi-
tions with altered consciousness in transplant recipients 
depends on the time elapsed since transplantation. Anoxic 
brain injury is associated with the intraoperative proce-
dure, and toxic and metabolic disturbances. Opportunistic 
infections are the most common complications causing 
altered consciousness38.
Central pontine myelinolysis
Central pontine myelinolysis (CPM) is a non-inflam-
matory demyelinating disease of the pons, most com-
monly found in patients with chronic medical conditions 
such as alcohol dependence and often occurring following 
a rapid increase in serum sodium concentration4. A high 
proportion of post-transplant CPM cases can be traced to 
rapid correction of hyponatremia, often in the periopera-
tive period or in association with high levels of cyclospo-
rin A. The classic clinical spectrum of CPM is comprised of 
acute onset of tetraparesis, pseudobulbar palsy, dysphagia 
and stupor. The MRI shows lesions in the pons, which are 
hypointense on T1 and hyperintense on T2 and diffusion-
weighted sequences (Figure 7). There is no specific therapy 
to reverse CPM38.
Figure 6. Brain MRI shows an expansive lesion with gadolinium 
enhancement in the cerebellum. Biopsy confirmed central 
nervous system post-transplant lymphoproliferative 
disorders (PTLD).
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Graft-versus-host disease 
Graft-versus-host disease is an immunological disorder 
caused when donor lymphocytes attack recipient tissues. 
This syndrome can affect many organ systems including 
the central and peripheral nervous systems. Neurological 
complications are seen almost exclusively in chronic graft-
versus-host disease and include cerebral angiitis, cerebral 
lymphomononuclear infiltrates, polymyositis, and myas-
thenia gravis. Patients with CNS involvement of chronic 
graft-versus-host disease may present with seizures or 
focal neurological signs38.
Table 3. Main neurological effects related to immunosuppressive agents in solid organ transplant patients.
Drugs Neurological side effects
Antiproliferative agents
Mycophenolate mofetil or sodium Peripheral neuropathy, aseptic meningitis and PML  
Azathioprine Seizures
Calcineurin inhibitors
Cyclosporin A
Myalgia and cramps, peripheral neuropathy, reflex sympathetic dystrophy, acute 
toxic encephalopathy, tremor, chorea, cerebellar ataxia, seizures, headache, 
depression and episodes of mania, sleep-wake cycle changes (insomnia), akinetic 
mutism and PRES
Tacrolimus   
All related to cyclosporin A and the following: sensorineural hearing loss, 
central osmotic demyelination, optic neuropathy and CIDP-like syndrome 
and brachial plexopathy
Non-calcineurin inhibitors of proliferation sign
Sirolimus     PRES, acute confusional syndrome, headache
Everolimus   Vertigo, tremor, hypoesthesia, paresthesia and somnolence
Corticosteroids Psychiatric disorders, tremor, seizures, headache, pseudotumor cerebri and myopathy 
Monoclonal antibodies (rituximab) PML, myalgia, dizziness, and headache dementia with or without aseptic meningitis
Polyclonal antibodies (antithymocyte globulin 
and antilymphocytic globulins) Opportunistic infections
Cyclophosphamide Toxic encephalopathy
Methotrexate  Necrotizing cerebral microangiopathy, visual loss, seizures, leukoencephalopathy, acute transverse myelitis (especially if intrathecal), hyperintense signal on brain MRI
Intravenous immunoglobulin Headache, diffuse paresthesias, myalgia, stroke, cerebral venous thrombosis and aseptic meningitis. Cases of Creutzfeldt-Jakob disease are described
PML: Progressive multifocal leukoencephalopathy; PRES: Posterior reversible encephalopathy syndrome; CIDP: Chronic inflammatory demyelinating 
polyradiculoneuropathy; MRI: Magnetic resonance imaging. 
Figure 7. Brain MRI discloses a hyperintense signal in the pons, in a transplant recipient (liver transplantation) with pontine myelinolysis.
Myelopathies
Spinal cord involvement in transplant recipients is an 
unusual neurological manifestation. Some causes of spinal 
cord lesions in transplant patients include epidural abscess, 
hematoma, and viral infections. Human T-lymphotropic 
virus 1, HHV-6, HHV-7, VZV, EBV or CMV infection can lead 
to myelopathy or polyradiculopathy38.
Movement disorders
Abnormal and involuntary movements after transplan-
tation are usually associated with drug treatment. Tremor is 
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frequently associated with the use of calcineurin inhibitors 
(tacrolimus and cyclosporine); Parkinsonism is associated with 
hepatocerebral degeneration and liver failure; and myoclonus 
is particularly associated with opiate and antidepressant use38.
Headache 
Headache is often an underrated condition in transplant 
patients because of overlapping of other neurological and 
systemic complications. However, a new onset headache can 
be the first clinical manifestation of an opportunistic infec-
tion, brain neoplastic condition or neurotoxicity. As well, cal-
cineurin inhibitors can aggravate pre-existing migraine38.
Visual and auditory disturbances
Visual disturbances can be a symptom of cortical blind-
ness associated with PRES and drug neurotoxicity. Ocular 
infections following fungal and viral infections require 
prompt treatment to prevent complications. Additionally, 
asymmetric bilateral demyelinating optic neuropathy can 
develop after tacrolimus use. Benign intracranial hyperten-
sion and optic disk edema has rarely been reported following 
renal transplantation38,39.
Sensorineural hearing loss can occur in patients under-
going liver or renal transplantation and has been reported in 
association with both tacrolimus and cyclosporine use38,39.
FINAL REMARKS
The variety of neurological manifestations following solid 
organ transplantation is broad and carries prognostic sig-
nificance. Patients may have involvement of the central or 
peripheral nervous system due to multiple causes that can 
vary depending on time of onset after the surgical procedure, 
the transplanted organ, and intensity and type of immuno-
suppressive therapy. Neurological manifestations following 
solid organ transplantation pose a diagnostic challenge to 
medical specialists despite extensive investigations. 
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